HDAC9 and autosomal dominant polycystic kidney disease: Additionally, the HDAC inhibitor vorinostat has been found to treat mechanisms similar to ADPKD pathogenic mechanisms, including increased renal size, extracellular matrix accumulation, and increased cell proliferation (Seeger-Nukpezah et al. 2015).